News
J&J's subcutaneous Rybrevant cleared by FDA
J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
News
Lilly points to long-lasting weight loss with orforglipron
Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.
News
Datroway filed for TNBC in EU after data delay
Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.
News
MSD claims two national priority vouchers; report
The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
Sales & Marketing
Marketing yourself isn’t selling out. It’s smart science.
The call lasted ten minutes. My manager was apologetic. HR was professional.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
